D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 71 Citations 23,218 281 World Ranking 15081 National Ranking 7871

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Acquired immunodeficiency syndrome
  • Disease

His scientific interests lie mostly in Internal medicine, Emtricitabine, Immunology, Efavirenz and Acquired immunodeficiency syndrome. His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Lipodystrophy and Endocrinology. His work carried out in the field of Emtricitabine brings together such families of science as Elvitegravir, Tenofovir alafenamide, Abacavir, Regimen and Cobicistat.

Paul E. Sax focuses mostly in the field of Immunology, narrowing it down to matters related to Pre-exposure prophylaxis and, in some cases, Intensive care medicine. His Efavirenz study integrates concerns from other disciplines, such as Atazanavir and Ritonavir. The concepts of his Acquired immunodeficiency syndrome study are interwoven with issues in Life expectancy, Quality-adjusted life year, Psychiatry and Disease.

His most cited work include:

  • Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia (1792 citations)
  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation (910 citations)
  • Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy (605 citations)

What are the main themes of his work throughout his whole career to date?

Paul E. Sax spends much of his time researching Internal medicine, Acquired immunodeficiency syndrome, Virology, Immunology and Antiretroviral therapy. His Internal medicine research includes themes of Efavirenz, Ritonavir, Oncology and Emtricitabine. His Ritonavir study incorporates themes from Darunavir, Atazanavir and Pharmacology.

His Emtricitabine study combines topics in areas such as Gastroenterology, Abacavir/Lamivudine and Tenofovir alafenamide. His Acquired immunodeficiency syndrome research includes elements of Disease and Family medicine. His Antiretroviral therapy research incorporates themes from Pediatrics and Intensive care medicine.

He most often published in these fields:

  • Internal medicine (34.70%)
  • Acquired immunodeficiency syndrome (19.24%)
  • Virology (14.67%)

What were the highlights of his more recent work (between 2015-2021)?

  • Internal medicine (34.70%)
  • Dolutegravir (5.21%)
  • Emtricitabine (7.89%)

In recent papers he was focusing on the following fields of study:

Paul E. Sax mainly investigates Internal medicine, Dolutegravir, Emtricitabine, Clinical trial and Regimen. Paul E. Sax combines subjects such as Gastroenterology, Lamivudine and Acquired immunodeficiency syndrome with his study of Internal medicine. His studies in Dolutegravir integrate themes in fields like Integrase inhibitor, Pharmacotherapy, Drug resistance and Virology.

His research in Emtricitabine intersects with topics in Efavirenz, Elvitegravir, Tenofovir alafenamide and Coinfection. His work investigates the relationship between Clinical trial and topics such as Viral load that intersect with problems in Viremia and Viral suppression. His Life expectancy research focuses on Mean age and how it connects with Immunology.

Between 2015 and 2021, his most popular works were:

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel (414 citations)
  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel (310 citations)
  • Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial (127 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Acquired immunodeficiency syndrome
  • Disease

Paul E. Sax mainly investigates Internal medicine, Dolutegravir, Regimen, Randomized controlled trial and Emtricitabine. His work deals with themes such as Gastroenterology, Darunavir, Oncology and Ritonavir, which intersect with Internal medicine. His Dolutegravir research is multidisciplinary, relying on both Integrase inhibitor and Viral load.

The Regimen study combines topics in areas such as Cohort study, Stroke, Clinical endpoint, Disease and Atazanavir. His research in Randomized controlled trial focuses on subjects like Lamivudine, which are connected to Clinical trial and Pediatrics. His research investigates the connection with Emtricitabine and areas like Tenofovir alafenamide which intersect with concerns in Bictegravir, Pharmacology, Cobicistat, Pre-exposure prophylaxis and Intensive care medicine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

Eric S. Rosenberg;James M. Billingsley;Angela M. Caliendo;Steven L. Boswell.
Science (1997)

2892 Citations

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

Pereyra F;Jia X;McLaren Pj.
Science (2010)

1350 Citations

Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy

Colleen Hadigan;James B. Meigs;Colleen Corcoran;Petra Rietschel.
Clinical Infectious Diseases (2001)

851 Citations

The Survival Benefits of AIDS Treatment in the United States

Rochelle P. Walensky;Rochelle P. Walensky;A. David Paltiel;Elena Losina;Lauren M. Mercincavage.
The Journal of Infectious Diseases (2006)

685 Citations

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel

Huldrych F. Günthard;Michael S. Saag;Constance A. Benson;Carlos del Rio.
JAMA (2016)

637 Citations

The lifetime cost of current human immunodeficiency virus care in the United States.

Bruce R. Schackman;Kelly A. Gebo;Rochelle P. Walensky;Elena Losina.
Medical Care (2006)

571 Citations

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

Grace A. McComsey;Douglas Kitch;Eric S. Daar;Camlin Tierney.
The Journal of Infectious Diseases (2011)

570 Citations

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Paul E Sax;David Wohl;Michael T Yin;Frank Post.
The Lancet (2015)

542 Citations

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Paul E. Sax;Edwin DeJesus;Anthony Mills;Andrew Zolopa.
The Lancet (2012)

539 Citations

Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection

Marcus Altfeld;Eric S. Rosenberg;Raj Shankarappa;Joia S. Mukherjee.
Journal of Experimental Medicine (2001)

495 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Paul E. Sax

Bruce D. Walker

Bruce D. Walker

Harvard University

Publications: 265

Kenneth H. Mayer

Kenneth H. Mayer

Fenway Health

Publications: 114

Philip J. R. Goulder

Philip J. R. Goulder

University of Oxford

Publications: 94

Grace A. McComsey

Grace A. McComsey

Case Western Reserve University

Publications: 90

Eric S. Rosenberg

Eric S. Rosenberg

Harvard University

Publications: 87

Steven K. Grinspoon

Steven K. Grinspoon

Harvard University

Publications: 86

Steven G. Deeks

Steven G. Deeks

University of California, San Francisco

Publications: 80

David A. Cooper

David A. Cooper

Pfizer (United States)

Publications: 76

Julio S. G. Montaner

Julio S. G. Montaner

University of British Columbia

Publications: 75

Marcus Altfeld

Marcus Altfeld

Heinrich-Pette-Institute

Publications: 72

Mary Carrington

Mary Carrington

Ragon Institute of MGH, MIT and Harvard

Publications: 69

Pere Domingo

Pere Domingo

Autonomous University of Barcelona

Publications: 63

Kenneth A. Freedberg

Kenneth A. Freedberg

Harvard University

Publications: 63

Jens D. Lundgren

Jens D. Lundgren

Rigshospitalet

Publications: 62

Rochelle P. Walensky

Rochelle P. Walensky

Harvard University

Publications: 60

Joseph J. Eron

Joseph J. Eron

University of North Carolina at Chapel Hill

Publications: 60

Something went wrong. Please try again later.